Mankind Pharma Q2 FY27 Earnings Call: PAT Jumps 38% YoY, Outperformance Guidance Trimmed

Mankind Pharma Ltd held its Q2 FY27 earnings call on October 26, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Beat on Margins and Earnings

• Revenue of Rs.4,338 Cr, +17.3% YoY — vs Rs.3,697 Cr in Q2 FY 2025-2026, driven by the base business and BSV specialty business; EBITDA of Rs.1,175 Cr grew 27.2% YoY.
• PAT of Rs.716 Cr, +37.7% YoY — PAT margin of 16.5% (+240 bps); diluted EPS Rs.17.2, cash EPS Rs.22.9 (+29.1% YoY).
• Gross margin expanded 90 bps YoY to 72.2% — on price increases, favorable chronic mix (+80 bps YoY), and a favorable base as Q2 FY 2025-2026 was compressed by GST 2.0 transition.
• EBITDA margin bridge of +210 bps — 90 bps gross margin, 40 bps lower R&D expense, 80 bps operating leverage; H1 FY 2026-2027 EBITDA margin at 26.7%, +230 bps YoY.
• Effective tax rate rose to 24% in H1 FY 2026-2027 — vs 17.1% in H1 FY 2025-2026, due to adoption of the new tax regime after expiry of the tax exemption period.
• TTM net operating working capital rose to 51 days — from 46 days a year ago; H1 FY 2026-2027 operating cash flow of Rs.1,819 Cr (+11.1% YoY), cash flow-to-EBITDA at 81% vs 92% on higher working capital.

Volume-Led Recovery, But Outperformance Guidance Trimmed

• India RX grew 16% in Q2 FY 2026-2027 — aided by a low base (Q2 FY 2025-2026 grew 5%); two-year CAGR ~11%, still below IPM's current 12-13% growth (framing by analyst Rahul Jivani, IIFL).
• Volume growth trajectory improved steadily — from -0.5% in Q2 FY 2025-2026 to 6.2% in Q2 FY 2026-2027 (per Rajeev Juneja); IQVIA secondary sales grew 15.7%, a 1.1x outperformance vs IPM's 14.2% (ex-temzibutide).
• Outperformance guidance of ~1.1-1.2x IPM for Q3-Q4 FY 2026-2027 — below the historical 1.3-1.4x, with management flagging unpredictability in IPM growth over the next 2-3 quarters (Q3 FY 2026-2027 to Q1 FY 2027-2028).
• Management did not commit to a specific India growth number — on a sustainable 11-12% trajectory, it stated only that Mankind will outperform IPM; Prakash Agarwal said field-force disruption of the past 6-8 quarters has stabilized over the last 3-4 quarters.
• Chronic share (ex-BSV) at 37.4%, +80 bps YoY — 1.1x outperformance in cardio and anti-diabetes (ex-teriparatide), 1.9x in chronic respiratory; anti-infectives recovering (5.4% in Q2 FY 2026-2027 vs 3.6% in Q1 FY 2026-2027), expected to match IPM from Q3 FY 2026-2027 onward.
• MR productivity improved to ~Rs.7.4 lakh TTM — from ~Rs.7 lakh in FY 2025-2026, despite headcount addition; ~7% MR addition guidance for FY 2026-2027 reaffirmed and on track (FY 2028-2029 MR guidance to be shared in FY 2027-2028).
• Brand portfolio scaled up — 63 brand families over Rs.50 Cr in MAT September 2026 (vs 54 in FY 2025-2026) and 26 families over Rs.100 Cr (vs 22); newer brands Monarom, Empagrit, DynoDUE, Neurocrine PFS and Pentanidra in early lifecycle stages.

Guidance Trimmed; Management Expects FY28 Recovery

• FY 2026-2027 consumer growth guided at high single digit — below the earlier high single digit-to-low double digit guidance; consumer revenue was Rs.229 Cr in Q2 FY 2026-2027, impacted by slower industry category offtake and regional impact in East and South.
• Management expects recovery over the next 3-6 months (within FY 2026-2027) and especially in FY 2027-2028 — Rajeev Juneja emphatically affirmed the FY28 recovery ("Absolutely, 100%") and said transformative changes will be rolled out on the consumer side over the next few months within FY 2026-2027.
• E-commerce grew 100% — now ~15% of consumer sales (Q2 FY 2026-2027 run-rate); modern trade and e-commerce share rose to 18% from 12% in Q2 FY26, supported by 55% growth in that channel; these sales are booked within the consumer segment, not domestic Rx.
• OTC defense — Rajeev Juneja rejected the "sluggish OTC" characterization, citing a "double digit plus" OTC CAGR (period unspecified), a 25% decline (period unspecified) and 10% growth last year (FY 2026-2027).
• Launch economics favor migration — more than 90% of new consumer launches fail (single-digit success rate), so the strategy is migrating proven OTX prescription brands (HealthOK, Acristar; Gaso Fast a strong current performer); no committed timeline for larger new OTC brands to break out.

Exports Running Well Ahead of Guidance

• International revenue grew 33% YoY to Rs.680 Cr in Q2 FY 2026-2027 — vs FY 2026-2027 export guidance of 20% growth (CC, dollar basis); Q2 actual growth is running above 30%, with the delta driven by currency exchange benefit (Arjun Juneja, COO).
• Segment split in Q2 FY 2026-2027 — BSV grew 34%, Mankind US 29%, other international markets 37%; BSV portfolio sustained 20% growth for the second consecutive quarter.
• International mix is shifting — the US, which contributed 70-75% of exports 1-2 years ago, now contributes roughly equally with other branded markets; management expects other emerging markets to overtake the US in contribution going forward (period unspecified).
• BSV mandate brands grew 20-25% over the last four quarters through Q2 FY 2026-2027 — top three brands at 30-40%; drivers include demand-creation for Anti-D, expanded IVF clinic coverage (including Indira and other chains), and clinical work on Anti-D, Foligraf and Histoglow; gynac coverage expanded from 33,000 to 37,000 doctors over 18-24 months. On sustainability, management said "we hope so" — no firm forward guidance.
• ROW emerging markets span four clusters — ASEAN (Philippines the larger market), MENA Africa, RCIS and LATAM; BSB is more an emerging-market play than a specialty one, with growth from deeper penetration and existing products entering newer markets.

CAR-T Acquisition, GLP-1 Entry, UCPMP and Tax Litigation

• Strategic acquisition of Arm Cell Therapeutics announced — provides access to a next-generation CAR-T cell therapy platform; management views this as a step toward building an innovation platform for future growth.
• MKP11093, a best-in-class JAK inhibitor, received funding — under the Government of India's PRIP program, a first for Mankind; ACTX funding commitment under the business plan is 48 million (currency not specified), good up to fiscal year 2028, with clinical trial results expected over the next 2 years; post-FY28 options include "partnerships, self-funding the R&D programs, or a combination," contingent on good results.
• GLP-1/semaglutide entry begins — management deliberately delayed entry until competitor pricing became "common and sensible"; work has begun with one launch in cardio-diabetes and one in Gyanix.
• UCPMP readiness — Rajeev Juneja noted the UCPMP guideline has existed for 3-4 years on a voluntary basis and that with the Supreme Court ruling, the government wants it to have more statutory powers; a Supreme Court-mandated committee on marketing practices has a hearing scheduled on 29th Jan 2027. Mankind has been preparing for 7-8 years and is "fully geared up" to comply with whatever the committee recommends.
• Section 37-1 tax litigation of Rs.1,609 Cr disallowance — the Commissioner of Appeals quashed the four years under dispute, reducing overall tax exposure by ~Rs.300 Cr; the provision and payout are fully accounted for, and no change to financial metrics is expected.

Guidance Held Despite the Beat; Debt Paydown on Track

• FY 2026-2027 margin guidance maintained at 25.5%-26.5% — CFO Ashutosh Dhawan declined to upgrade despite Q2 tracking at the higher end (~27%); on whether 100 bps of annual expansion is fair or 27-28% is peak, he said the direction is "fundamentally and directionally correct" but reliable guidance will come with the FY 2027-2028 data point.
• FY 2026-2027 R&D spend expected near 3% of revenue — at the upper end of the 2.8%-3% guidance, accounting for the impact of ACTX (Q2 ran at 2.5% of sales, Rs.108 Cr).
• Capex of Rs.214 Cr in Q2 FY 2026-2027 (4.9% of revenue) — below the FY 2026-2027 guidance of 6-7% of revenue.
• Net debt reduced to Rs.2,639 Cr as of 30 September 2026 — net debt-to-adjusted EBITDA of 0.6x (TTM); management remains on track to repay acquisition-related debt by FY 2027-2028.
• Chronic mix ambition of 50% — management reiterated its commitment ("We stick to that") to increasing chronic share from 39% to 50% (period unspecified); Prakash Agarwal set a 4-5 year ambition to touch 50% chronic mix (≈ FY 2030-31 to FY 2031-32), adding 100-200 bps per year.
• Weak monsoon impact acknowledged but not significant — per Rajeev Juneja, Q2 FY 2026-2027 growth was dominated by the chronic portfolio and, to some extent, gastro and multivitamins, which are not season-dependent; hospital revenues grew 23% YoY with broad-based growth across metros, tier one and tier two cities.